Innovation in Psychiatric Drug Development
The Journal of Clinical Psychiatry · 2026
DOI: 10.4088/jcp.25m16063 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift The Journal of Clinical Psychiatry, 2026. Verfasst von John Havlik und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, California. Hauptthemen laut MEDLINE: Drug Development, Drug Approval, Psychotropic Drugs, Mental Disorders. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, California.
- Corresponding Author: John Havlik, MD, MBA, 401 Quarry Rd, Rm 1211, Palo Alto, CA 94304 (jhavlik@stanford.edu).
- The University of Chicago, Chicago, Illinois.
- Department of Psychiatry, Veterans Affairs Palo Alto Health Care System, Palo Alto, California.
- Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut.
- Department of Public Health Sciences, University of Connecticut School of Medicine, Farmington, Connecticut.
Zitieren
APA
Havlik, J., Isaac, S., Radovan, C., Ostacher, M. J., Smith, D., & Rhee, T. G. (2026). Innovation in Psychiatric Drug Development. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.25m16063
Vancouver
Havlik J, Isaac S, Radovan C, Ostacher MJ, Smith D, Rhee TG. Innovation in Psychiatric Drug Development. The Journal of Clinical Psychiatry. 2026. doi:10.4088/jcp.25m16063
BibTeX
@article{Havlik2026,
author = {Havlik, John and Isaac, Sayana and Radovan, Caitlin and Ostacher, Michael J and Smith, David and Rhee, Taeho Greg},
title = {Innovation in Psychiatric Drug Development},
journal = {The Journal of Clinical Psychiatry},
year = {2026},
doi = {10.4088/jcp.25m16063}
}
EUVIMED